ProQR Therapeutics (PRQR) Non-Current Assets (2013 - 2026)
ProQR Therapeutics (PRQR) posted Non-Current Assets of $14.1 million for Q1 2026, down 4.03% sequentially from $14.7 million in Q4 2025, and down 1.43% YoY from $14.3 million in Q1 2025.
ProQR Therapeutics (PRQR) Non-Current Assets (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported Non-Current Assets for 14 years, with the latest figure at $14.1 million in Q1 2026.
- Quarterly Non-Current Assets fell 1.43% year-over-year to $14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.0 million (down 5.97% YoY) and the FY2025 annual result came in at $14.7 million, down 2.51% from the prior year.
- Non-Current Assets eased to $14.1 million in Q1 2026 per PRQR's latest filing, from $14.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $19.9 million in Q1 2022 and troughed at $14.1 million in Q1 2026.
- A 5-year average of $16.9 million and a median of $17.5 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets sank 99.98% in 2022, then climbed 6.24% in 2023.
- Over 5 years, Non-Current Assets stood at $17.2 million in 2022, then increased by 5.68% to $18.2 million in 2023, then slipped by 17.05% to $15.1 million in 2024, then declined by 2.51% to $14.7 million in 2025, then decreased by 4.03% to $14.1 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $14.1 million, $14.7 million, and $15.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | 14.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.11 Mn |
| Dec 31, 2025 | 14.70 Mn |
| Sep 30, 2025 | 15.22 Mn |
| Jun 30, 2025 | 15.01 Mn |
| Mar 31, 2025 | 14.31 Mn |
| Dec 31, 2024 | 15.08 Mn |
| Sep 30, 2024 | 15.85 Mn |
| Jun 30, 2024 | 17.54 Mn |
| Mar 31, 2024 | 18.17 Mn |
| Dec 31, 2023 | 18.18 Mn |
| Sep 30, 2023 | 18.88 Mn |
| Jun 30, 2023 | 18.34 Mn |
| Mar 31, 2023 | 17.60 Mn |
| Dec 31, 2022 | 17.20 Mn |
| Sep 30, 2022 | 17.77 Mn |
| Jun 30, 2022 | 19.20 Mn |
| Mar 31, 2022 | 19.93 Mn |
| Dec 31, 2021 | 20.70 Mn |
| Sep 30, 2021 | 21.55 Mn |
| Jun 30, 2021 | 22.61 Mn |